Would you recommend the following article to a politician, an athlete, a business executive, or a scientist?

AstraZeneca to take earnings hit on drug rejection AstraZeneca will have to take a charge against 2004 earnings after US regulators rejected its new anti-clotting drug Exanta, but a company spokesman has declined to say how large it will be.
